Jinshi Asia Pharmaceutical Subsidiary Dier Pharmaceutical's Diclofenac Sodium Sustained-Release Tablets Proposed for Centralized Procurement

Corporate Action
โดย 财中社·Read original
Summary · why it matters

Jinshi Asia Pharmaceutical's wholly-owned second-tier subsidiary, Zhejiang Dier Pharmaceutical Co., Ltd., has had its diclofenac sodium sustained-release tablets proposed for selection in the 12th round of national centralized drug procurement. The proposed selected product generated sales revenue of 6.2231 million yuan in 2025 for the same specification, accounting for 0.60% of the company's 2025 operating revenue. Total 2025 sales revenue for the full diclofenac sodium sustained-release tablet category was 38.1834 million yuan, representing 3.68% of the company's 2025 operating revenue. In the first quarter of 2026, Jinshi Asia Pharmaceutical achieved revenue of 331 million yuan and net profit attributable to the parent company of 116 million yuan.

Impact on stocks 2

Others▲ · 2 stocks

Off-coverage companies 1

Zhejiang Dier Pharmaceutical Co., Ltd.Private▲ Positive
Demandrelevance

Dier Pharmaceutical's product proposed for selection in centralized procurement, boosting demand.

© 2026 MarketDXNews